[REVISION HISTORY]
Global RSV prevention and immunization efforts
13 recorded revisions of this situation.
What changed
2026-11-14 08:21 UTC → 2026-11-16 19:01 UTC ·
added
removed
Public health authorities are implementing expanded strategies to combat Respiratory Syncytial Virus (RSV) for the 2026–2027 season. In the United Arab Emirates, the Ministry of Health and Prevention has broadened its respiratory disease awareness campaign to include RSV alongside influenza, targeting high-risk groups like pregnant women and older adults. In Dubai, the Dubai Health Authority has issued updated clinical guidelines requiring healthcare providers to verify vaccination status during clinical visits, specifically prioritizing individuals with chronic cardiac, pulmonary, renal, liver, or neurodevelopmental diseases, as well as pilgrims for Hajj and Umrah. Clinical data continues to support various interventions. In Austria, research from the Graz Women’s and Children’s Clinics confirmed that RSV immunization significantly reduces infant hospitalization risk, showing a 77 percent reduction in risk compared to non-immunized infants. However, in Vienna, medical professionals noted that while some vaccinations are free, RSV immunization currently requires out-of-pocket payment, which is a concern for oncology patients with weakened immune systems. In Poland, Professor Piotr Rzymski stated that RSV vaccination protects against severe lower respiratory tract infections for at least three infectious seasons. New research published in The Lancet suggests that RSV immunization, specifically via the monoclonal antibody Nirsevimab, may provide secondary protection against invasive pneumococcal infections, with a study in France observing a 36 percent decrease in such hospitalizations among children. In Italy, experts are calling for RSV vaccines to be included in the National Vaccination Prevention Plan to ensure uniform access, noting that the virus causes significant annual mortality among those aged 60 and over. In Spain, a multicenter study in Andalusia involving the University Hospital of Jaén and eight other pediatric hospitals has confirmed that nirsevimab significantly reduces RSV-related hospitalizations in infants. Published in the journal Pediatrics, the research indicates that protective benefits extend into the child’s second year of life.
Versions
- 2026-11-16 19:01 UTC Global RSV prevention and immunization efforts
- 2026-11-14 08:21 UTC Global RSV prevention and immunization efforts
- 2026-11-04 14:05 UTC Global RSV prevention and immunization efforts
- 2026-11-03 22:07 UTC Global RSV prevention and immunization efforts
- 2026-11-03 20:22 UTC Global RSV prevention and immunization efforts
- 2026-11-03 18:08 UTC Global RSV prevention and immunization efforts
- 2026-11-03 09:23 UTC Global RSV prevention and immunization efforts
- 2026-10-31 08:45 UTC Global RSV prevention and immunization efforts
- 2026-10-29 13:23 UTC Global RSV prevention and immunization efforts
- 2026-10-22 01:51 UTC Global RSV prevention and immunization efforts
- 2026-10-10 03:30 UTC Global RSV prevention and immunization efforts
- 2026-10-09 12:22 UTC Global RSV prevention and immunization efforts
- 2026-09-27 15:58 UTC Global RSV prevention and immunization efforts
- 2026-09-18 12:31 UTC Global RSV prevention and immunization efforts
Select a version to see what changed compared to the one before it.